已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

OCT guided vs. COmplete pci in patieNts with sT segment elevation myocArdial infarCtion and mulTivessel disease: OCT-CONTACT RCT

医学 传统PCI 心脏病学 经皮冠状动脉介入治疗 心肌梗塞 内科学 狼牙棒 罪魁祸首 部分流量储备 随机对照试验 血运重建 临床终点 冠状动脉造影
作者
Mario Iannaccone,Ovidio De Filippo,Andrea Montabone,Giorgio Marengo,Ludovica Maltese,Fabrizio Ugo,Giorgio Quadri,Maro MENNUNI,Gioel Gabrio Secco,Vittorio Taglialatela,Sebastian Cinconze,Claudio Moretti,Alessandra Truffa,Alfonso Gambino,Giacomo Boccuzzi,Vincenzo Infantino,Federico Conrotto,Alessandro Lupi,Ferdinando Varbella,Giuseppe Patti
出处
期刊:Minerva cardiology and angiology [Edizioni Minerva Medica]
卷期号:71 (4) 被引量:4
标识
DOI:10.23736/s2724-5683.22.06144-0
摘要

In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significantly reduces the risk of cardiovascular death. However, the management of non-culprit lesions in patients with the multivessel disease remains a matter of debate in this setting. It's still unclear if a morphological OCT-guided approach, identifying coronary plaque instability, may provide a more specific treatment compared with a standard angiographic/functional approach.OCT-Contact is a prospective, multicenter, open-label, non-inferiority randomized controlled trial. Patients with STEMI with successful primary PCI of the culprit lesion will be enrolled after the index PCI. Patients will be deemed eligible if a critical coronary lesion other than the culprit (associated with a diameter of stenosis ≥50%) will be identified during the index angiography. Patients will be randomized in a 1:1 fashion to OCT-guided PCI of non-culprit lesions (Group A) vs. complete PCI (Group B). PCI in group A will be undertaken according to criteria of plaque vulnerability, while in group B the use of fractional flow reserve will be left at the operators' discretion. Major-adverse cardiovascular events (MACE) are a composite of all-cause mortality, non-fatal myocardial infarction (MI) (excluding peri-procedural MI), unplanned revascularization, and NYHA IV heart failure) will be the primary efficacy outcome. Single components of MACE along with cardiovascular mortality will be the secondary endpoints. . Safety endpoints will embrace worsening of renal failure, procedural complications, and bleedings. Patients will be followed for 24 months after randomization.A sample size of 406 patients (203 per group) is required to provide the analysis an 80% power to detect a non-inferiority in the primary endpoint with an alpha error set at 0.05 and a non-inferiority limit of 4%.A morphological OCT-guided approach may be a more specific treatment compared with the standard angiographic/functional approach in non-culprit lesions of STEMI patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
明月朗晴完成签到 ,获得积分10
刚刚
六六发布了新的文献求助30
1秒前
he发布了新的文献求助20
1秒前
木子完成签到,获得积分10
1秒前
cqsz完成签到,获得积分10
2秒前
3秒前
CipherSage应助科研通管家采纳,获得10
3秒前
超级摩托发布了新的文献求助10
3秒前
molihuakai应助科研通管家采纳,获得10
3秒前
共享精神应助科研通管家采纳,获得10
3秒前
3秒前
酷波er应助科研通管家采纳,获得10
3秒前
完美世界应助科研通管家采纳,获得10
4秒前
4秒前
池雨完成签到 ,获得积分10
4秒前
4秒前
木子发布了新的文献求助10
4秒前
快乐芷荷完成签到 ,获得积分10
5秒前
核桃应助风清扬采纳,获得20
6秒前
LiChard完成签到 ,获得积分0
8秒前
11秒前
赘婿应助eulota采纳,获得30
13秒前
核桃应助风清扬采纳,获得20
15秒前
白火完成签到,获得积分10
16秒前
七月完成签到 ,获得积分10
16秒前
16秒前
清秀小霸王完成签到 ,获得积分10
16秒前
zuo发布了新的文献求助10
18秒前
开心的万天完成签到,获得积分10
18秒前
七月关注了科研通微信公众号
21秒前
姜姜姜姜完成签到 ,获得积分10
24秒前
什么芝士蛋糕完成签到 ,获得积分10
25秒前
FrozenMask完成签到 ,获得积分10
26秒前
27秒前
adam完成签到 ,获得积分0
27秒前
冷静新烟发布了新的文献求助10
27秒前
核桃应助风清扬采纳,获得20
32秒前
苏打完成签到 ,获得积分10
33秒前
好人一生平安完成签到 ,获得积分10
33秒前
Lily完成签到 ,获得积分10
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Salmon nasal cartilage-derived proteoglycan complexes influence the gut microbiota and bacterial metabolites in mice 2000
The Composition and Relative Chronology of Dynasties 16 and 17 in Egypt 1500
Cowries - A Guide to the Gastropod Family Cypraeidae 1200
ON THE THEORY OF BIRATIONAL BLOWING-UP 666
Signals, Systems, and Signal Processing 610
LASER: A Phase 2 Trial of 177 Lu-PSMA-617 as Systemic Therapy for RCC 520
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6380897
求助须知:如何正确求助?哪些是违规求助? 8193229
关于积分的说明 17316998
捐赠科研通 5434297
什么是DOI,文献DOI怎么找? 2874555
邀请新用户注册赠送积分活动 1851314
关于科研通互助平台的介绍 1696120